Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.34 |
| ▸ | MEN1 | O00255 | 2/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.32 |
| ▸ | HPGD | P15428 | 2/20 | 0.32 |
| ▸ | BDKRB1 | P46663 | 3/20 | 0.32 |
| ▸ | HTT | P42858 | 1/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
| ▸ | TACR1 | P25103 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13063135 | 0.85 | CYP3A4 (0.32) | CYP3A4HPGD | |
| SCHEMBL12012115 | 0.80 | BDKRB1 (0.40) | KMT2AMEN1TSHRBDKRB1HTT | |
| SCHEMBL12046796 | 0.79 | HTT (0.44) | TDP1KMT2AMEN1TSHRCYP3A4 | |
| SCHEMBL13063415 | 0.78 | MEN1 (0.34) | TDP1KMT2AMEN1BDKRB1HTT | |
| SCHEMBL3440233 | 0.77 | BDKRB1 (0.52) | BDKRB1 | |
| SCHEMBL13063372 | 0.76 | KEAP1 (0.41) | KMT2AMEN1TSHRCYP3A4HPGD | |
| SCHEMBL13063136 | 0.75 | LMNA (0.35) | KMT2AMEN1TSHRCYP3A4HPGD | |
| SCHEMBL13063122 | 0.74 | BDKRB1 (0.33) | KMT2AMEN1TSHRBDKRB1POLB | |
| SCHEMBL13063123 | 0.72 | ALDH1A1 (0.32) | KMT2AMEN1CYP3A4HPGDPOLB | |
| SCHEMBL13063117 | 0.72 | CYP3A4 (0.40) | KMT2AMEN1TSHRCYP3A4HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7858618-B2 | Compounds | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-12-28 | — | — | US | disclosed |
| US-20090137545-A1 | Compounds | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-05-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090137545-A1 | Compounds | ADORA2B, ABCB11, CYP11B1 | TDP1 2189/4885KMT2A 4086/4885MEN1 434/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.